CD84/SLAMF5 Antibody (CD84.1.21) [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # NB100-65929H
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, Immunoprecipitation
Label
HRP
Antibody Source
Monoclonal Mouse IgG1 Clone # CD84.1.21
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse pre-B cell line 300.19 transfected with CD84 cDNA
Localization
Type I membrane protein
Specificity
NB100-65929 recognizes the human CD84 cell surface antigen, a highly glycosylated cell surface antigen of 64-82kD. CD84 is predominantly expressed by B lymphocytes, monocytes and macrophages, although lower levels of expression have also been reported on T cells, granulocytes and platelets.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for CD84/SLAMF5 Antibody (CD84.1.21) [HRP]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD84/SLAMF5
Long Name
SLAM Family Member 5
Alternate Names
CD84, Ly-9B, SLAMF5
Gene Symbol
CD84
Additional CD84/SLAMF5 Products
Product Documents for CD84/SLAMF5 Antibody (CD84.1.21) [HRP]
Product Specific Notices for CD84/SLAMF5 Antibody (CD84.1.21) [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...